» Articles » PMID: 14745459

Blood-brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model

Overview
Date 2004 Jan 28
PMID 14745459
Citations 171
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To establish the generality of cerebrovascular pathology frequently observed with Alzheimer disease, we have assessed blood-brain barrier (BBB) integrity using the Alzheimer disease model Tg2576 mice in which cognitive deficits and neuritic plaque formation develop around 10-12 months of age.

Methods: We assessed BBB integrity using well-established methods involving albumin and Evans blue uptake and introduce the use of a novel perfusion protocol using succinimidyl ester of carboxyfluorescein diacetate.

Results: BBB permeability is increased in the cerebral cortex of 10-month-old Tg2576 mice preceding Alzheimer disease pathology presentation. Furthermore, when compared with their nontransgenic littermates, 4-month-old Tg2576 mice exhibit compromised BBB integrity in some areas of the cerebral cortex. An age-related increase in albumin uptake by the brains of Tg2576 mice, compared with nontransgenic mice, was also observed. These findings were supported by quantitative Evans blue analysis (p = 0.07, two-way analysis of variance).

Conclusion: A breakdown of BBB was evident in young 4- to 10-month-old Tg2576 mice. Compromised barrier function could explain the mechanisms of Abeta entry into the brain observed in experimental Alzheimer disease vaccination models. Such structural changes to the BBB caused by elevated Abeta could play a central role in Alzheimer disease development and might define an early point of intervention for designing effective therapy against the disease.

Citing Articles

The Cerebrovascular Side of Plasticity: Microvascular Architecture across Health and Neurodegenerative and Vascular Diseases.

Zedde M, Pascarella R Brain Sci. 2024; 14(10).

PMID: 39451997 PMC: 11506257. DOI: 10.3390/brainsci14100983.


Implications of microbe-derived ɣ-aminobutyric acid (GABA) in gut and brain barrier integrity and GABAergic signaling in Alzheimer's disease.

Conn K, Borsom E, Cope E Gut Microbes. 2024; 16(1):2371950.

PMID: 39008552 PMC: 11253888. DOI: 10.1080/19490976.2024.2371950.


Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy.

Zulinska S, Strosznajder A, Strosznajder J Int J Mol Sci. 2024; 25(13).

PMID: 39000217 PMC: 11241121. DOI: 10.3390/ijms25137106.


Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance.

Wu B, Liu Y, Li H, Zhu L, Zeng L, Zhang Z Neural Regen Res. 2024; 20(3):695-714.

PMID: 38886936 PMC: 11433892. DOI: 10.4103/1673-5374.391305.


Associations between regional blood-brain barrier permeability, aging, and Alzheimer's disease biomarkers in cognitively normal older adults.

Denkinger M, Baker S, Inglis B, Kobayashi S, Juarez A, Mason S PLoS One. 2024; 19(6):e0299764.

PMID: 38837947 PMC: 11152304. DOI: 10.1371/journal.pone.0299764.